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Radionuclide activities in the kidney and bladder have been estimated experimentally from
practical data 3 h after injection of Tc-99m MDP, using conjugate view methodology. The
study involved sixty-five patient images from the database of a nuclear medicine depart-
ment in Ghana. Timeeactivity curve was stimulated with MatLab computer program using
biokinetic model published in MIRD Report 13. The model was used to determine theo-
retical activities in kidney and bladder, which were compared with the experimental data.
Estimated radionuclide activities for the kidney and bladder were both minimal in the
experimental case comparative to the theoretical. The fraction of injected activity in kid-
ney and bladder were less than 1% of injected activity, and hence kidney and bladder could
be seen to receive very low doses during bone scans.
Copyright © 2015, The Egyptian Society of Radiation Sciences and Applications. Production
and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Nuclearmedicine is amedical specialty using radioisotopes as
tracers to diagnose diseases or for therapy. These tracers are
usually attached to chemical compounds that are attracted to
organs of interest such as bones or thyroid gland. After
administration into the body, tracers emit characteristic ra-
diations. Special electronic instruments, such as scintillation
detector or a gamma camera, displays the recorded emissionshysics Centre, Radiologic
hana.
aspee@gmail.com (F. Has
gyptian Society of Radiat
iety of Radiation Sciences
icense (http://creativecomas images. The images yield information about the anatomy
or the functional state of the organ being imaged.
In clinical applications of nuclear medicine, the amount of
administered activity is low such that its corresponding
absorbed dose to imaged and non-imaged tissues are typically
very low and thus stochastic effect are outweighed by the
diagnostic benefit of the imaging process (Bolch & Fahey,
2013). The role of internal dosimetry in diagnostic nuclear
medicine is thus to provide the basis for stochastic risk
quantification. Once this risk is quantified, it may be used toal and Medical Sciences Research Institute, Ghana Atomic Energy
ford).
ion Sciences and Applications.
andApplications. Production and hosting by Elsevier B.V. This is an
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maximize image quality while minimizing patient risk. This
optimization is considered, and always evaluated for any
imaging procedure (IAEA, 2011).
Accurate dosimetry of diagnostic procedures is important
formaking judgments on the diagnostic benefits to the patient
compared to the associated radiation risks. Dosimetry of
diagnostic radiopharmaceuticals is therefore primarily con-
cerned with the dosimetry of a total population or group
(Hickson, 2011). Image quantification in nuclear medicine is
used, among other options, to estimate activity in human
subjects for the calculation of radiation dose in individuals
undergoing radionuclide therapy and to study pharmacoki-
netics for approval of new radiopharmaceuticals (Pereira,
Stabin, Lima, Guimar~aes, & Forrester, 2010; Sgouros et al.,
2003).
The objective of this study is to determine the amount of
radionuclide activity in kidney and bladder of patients 3 h
after injection of technetium-99m (Tc-99m) in nuclear medi-
cine, using conjugate view approach.Table 1 e Transfer rate constants.
Radiopharmaceutical Tc-99m MDP
k12 0.063 ± 0.010
k21 0.295 ± 0.025
k31 0.305 ± 0.012
k43 3.25 ± 0.372. Methodology
Single photon emission computed tomography (SPECT) sys-
tem (Siemens, Germany) was used for performing bone scans
on patients as employed in studies by Yigbedeck et al. (2014)
and Hasford et al. (2015). The system was equipped with low
energy all purpose collimator and whole-body images ac-
quired 3 h post-injection of Tc-99mmethylene diphosphonate
(MDP). Quantitative analyses were performed on acquired
images by drawing regions of interest (ROIs) in the system's
e.soft software application, and tabulating counts of radio-
nuclide activity in the bladder and kidneys.
Whole-body bone scintigrams of 65 patients acquired with
the SPECT system were randomly selected for this study.
Computed tomography (CT) scans of 36 of the sampled pa-
tients were obtained and used in estimating average thick-
nesses of the organs of interest and their associated body
section. RadiAnt DICOM viewer software was used in
measuring the thicknesses in the anterior e posterior direc-
tion. Table A1 in Appendix A presents data on sampled pa-
tients' age, gender and administered activity.
Mean counts of activity in the kidney and bladder were
estimated using conjugate view methodology (Hasford et al.,
2015; Yigbedeck et al., 2014). Anterior and posterior counts of
activity were obtained from the scintigrams and geometric
mean count estimated using equation (1).
GMC ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
CA  CP
p
(1)
Counts of activitywere converted into radionuclide activity
(mCi) using Equation (2) (Pereira et al., 2010).
A ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
CA  CP
emet
r
 f
C
(2)
where, A is organ activity (mCi); CA and CP are the anterior and
posterior background corrected counts respectively; t is body
thickness across organ of interest (anterioreposterior); me is
effective linear attenuation coefficient of Tc-99m in softtissue; C is system calibration factor in counts per unit activ-
ity, expressed as fsource counts=known activityg; f represents
correction for the source region attenuation coefficient (me)
and source organ thickness (t) and is expressed as
fðmex=2Þ=sinhðmex=2Þg (J€onsson, 2007; Shahbazi-Gahrouei,
Cheki, & Moslehi, 2012; Siegel et al., 1999; Stabin, 2008).
Biokinetic model in MIRD Report 13 (Weber et al., 1989) was
used to simulate transfer of Tc-99m in the body with MatLab
program. The transfer of Tc-99m activity in blood, bone, kid-
ney and bladder was simulated by Equation (3)e(6).
dqBd
dt
¼ ðkR þ K21 þ k31ÞqBd þ k12qB0 (3)
dqB0
dt
¼ ðkR þ K12ÞqB0 þ k21qBd: (4)
dqKid
dt
¼ ðkR þ K43ÞqKid þ k31qBd (5)
dqUb
dt
¼ kRqUB þ K43qKid (6)
Table 1 presents transfer rate constants k12, k21, k31 and k43
specified in MIRD Report 13. Physical decay constant
kR ¼ 0.115 h1.
The resultant MatLab algorithm for the transfer of Tc-99m
activity in blood, bone, kidney and bladder is presented in
Appendix B:3. Results and discussion
3.1. Organ and body thickness
Estimated average thicknesses of kidney and bladder, and
their associated body sections for the 36 patients are sum-
marized in Table 2. The average thickness estimates for left
and right kidneys vary insignificantly by 4.2%. The measure-
ments of 4.92 cm and 5.14 cm for the left and right kidneys are
respectively consistent with study by Larsson et al. (2012). For
36 patients, the group estimated the thicknesses of left and
right kidneys to be 5.39 cm and 5.69 cm respectively. The
estimated average thicknesses in this study were used to
calculate attenuation coefficient of Tc-99m by conjugate view
approach.
3.1.1. Radionuclide activity in kidney and bladder
Average estimates for the radionuclide activity in the kidneys
and bladder 3 h after injection of Tc-99m MDP, and their
respective fractions of injected activity for the 65 patients are
presented in Table 3. Radionuclide activity in the kidneys
(0.041 ± 0.013 mCi) is much lesser than in the bladder
Table 2eAverage thicknesses of organs and body section
from CT scans.
Ant/Post thickness (mm)
Organ Body section
Left Kidney 49.23 ± 6.37 207.86 ± 34.26
Right Kidney 51.38 ± 5.66 207.97 ± 35.12
Bladder 37.19 ± 4.63 203.88 ± 40.12
Table 3 e Experimentally estimated radionuclide activity
in kidneys and bladder.
Organ Average activity
(mCi)
Fraction of injected
activity
Left Kidney 0.041 ± 0.013 0.22%
Right
Kidney
0.041 ± 0.012 0.22%
Bladder 0.132 ± 0.084 0.72%
Table 4 e Theoretically estimated radionuclide activity in
kidney and bladder.
Organ 3 h Post injection of Tc-99m MDP
Theoretically estimated
activity (mCi)
Fraction of injected
activity
Kidney 0.270 1.5%
Bladder 5.276 29.31%
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tivity estimated in kidney and bladder at 3 h post injection are
0.22% and 0.72% respectively. The injection of Tc-99m MDP
intravenously is mainly excreted in the form of urine through
the urinary system, of which kidney and bladder form part.
Kidney plays the role of blood filter and the bladder serves a
temporary storage reservoir for urine. Relatively high activity
recorded in bladder could be a result of the collection of large
quantity of urine which is subsequently eliminated through
the genitals.
3.2. Time-activity curve
Theoretically, timeeactivity curve for this study was obtained
fromMatLab stimulation of the biokinetic model published in
MIRD Report 13. The resultant MatLab algorithm is presented
in Appendix B. Plotted curves representing blood, bone, kid-
ney and bladder activities were generated from EquationFig. 1 e Time activity curve for Tc-99m MD(3)e(6) and presented in Fig. 1. Blood recorded significant
maximum radionuclide activity of 16.8 mCi at 0.1 h (6 min)
post injection of Tc-99m MDP. This results because the
radionuclide is directly injected into the blood stream where
emission of gamma rays begins to occur before the radionu-
clide reaches the bone, kidney and bladder. The activity curve
of blood decays with increasing time before Tc-99m begins to
emit gamma rays in the bone, kidney and bladder. Due to the
fact that the bladder acts as a reservoir for urine storage, Tc-
99m MDP stays in the bladder for a long period of time. The
bladder stores urine for approximately 6 h, thereby account-
ing for its highest activity of 5.35 mCi over kidney's activity of
1.08 mCi at 1 h post injection and bone's activity of 4.78 mCi at
4.3 h post injection.
Theoretically estimated radionuclide activity in kidney and
bladder 3 h after injection of Tc-99m MDP and their corre-
sponding fraction of injected activity are presented in Table 4.
High fraction of injected activity (29.31%) remains in the
bladder 3 h after injection.
3.3. Comparison of experimental and theoretical
radionuclide activities
Theoretically estimated radionuclide activities from stimula-
tion were considered as highest limit of activity for the organs
of interest in this study. Table 5 shows the experimentally and
theoretically estimated average radionuclide activities 3 h
after injection of Tc-99m MDP. Comparison of radionuclideP for blood, bone, kidney and bladder.
Table A1 e Bio data and injected activity of reported
patient.
Patient ID Age (yrs) Gender Injected activity (mCi)
1 56 M 19.5
2 68 M 17.4
3 60 M 17.9
4 56 M 18.0
5 55 M 19.2
6 37 F 17.9
7 67 M 17.3
8 70 M 18.3
9 65 M 16.8
10 71 F 18.8
11 62 M 16.1
12 61 M 17.2
13 66 M 15.5
14 59 F 15.8
15 73 M 15.3
16 73 M 16.7
17 58 F 15.4
18 63 F 18.5
19 80 M 16.5
Table 5 e Experimental and theoretical activity for kidney
and bladder.
Organs 3 h Post injection of Tc-99m MDP
Activity (mCi) Fraction of injected
activity (%)
Experimental Theoretical Experimental Theoretical
Kidney 0.041 0.270 0.22 1.5
Bladder 0.132 5.276 0.72 29.31
J o u r n a l o f R a d i a t i o n R e s e a r c h and A p p l i e d S c i e n c e s 8 ( 2 0 1 5 ) 3 1 7e3 2 2320activities depicts that the experimental estimates are
comparatively smaller than the theoretical estimates. Less
than 1% of the administered activity remained in the kidneys
and bladder 3 h after injection of Tc-99m MDP.
The theoretically estimated activity from simulation of
MIRD biokinetic model is considered as maximum limit in the
organs of interest because the model does not consider the
transfer rate from the bladder until urination. Due to this, high
activity estimates are observed 3 h after injection in the
theoretical case. Given that the simulated estimates are upper
limiting values, patients undergoing bone scan in this study
may be considered safe because of the low radionuclide ac-
tivities recorded in the kidney and bladder.20 66 F 20.8
21 83 M 20.0
22 68 M 23.5
23 71 F 20.7
24 64 F 21.1
25 50 F 24.7
26 59 M 20.8
27 86 M 20.7
28 66 M 24.5
29 73 M 22.5
30 60 M 21.2
31 63 F 20.6
32 78 M 22.7
33 61 F 22.0
34 57 M 23.1
35 58 M 20.7
36 62 M 21.34. Conclusion
Estimation of radionuclide activities in kidney and bladder are
considered necessary due the associated organ doses and risk
of cancer induction through late effects. Experimental and
theoretical estimates of activity show that kidney and bladder,
which are critical organs, each receive less than 1% fraction of
injected activity during nuclear medicine bone scans. The
fractions give indication that absorbed dose to the two organs
are typically very low and thus stochastic risks of cancer in-
duction may be greatly outweighed by diagnostic benefit of
the imaging procedure.37 41 F 22.6
38 36 F 13.4
39 65 M 14.9
40 37 F 19.0
41 67 M 16.1
42 54 F 14.1
43 74 M 15.95. Conflict of interest
No conflict of interest.44 38 F 11.5
45 25 F 12.5
46 63 M 13.4
47 60 M 19.1
48 45 F 17.6Acknowledgement
The studywas performed at a nuclearmedicine unit in Ghana.
The authors acknowledge with gratitude the support from the
department.Appendix A
Table A1 e (continued )
Patient ID Age (yrs) Gender Injected activity (mCi)
49 49 F 16.8
50 73 M 21.2
51 58 M 25.2
52 50 F 21.7
53 63 F 10.2
54 68 M 10.6
55 75 M 19.9
56 63 F 19.7
57 66 M 18.4
58 82 M 22.8
59 40 F 17.2
60 76 M 18.5
61 87 F 18.8
62 60 M 18.2
63 71 F 18.2
64 72 F 14.1
65 47 M 14.2
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MatLab algorithm for the transfer of Tc-99m activity in blood,
bone, kidney and bladder.r e f e r e n c e s
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